EcoDrugPlus

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSMMMG00000001006
Gene Symbol: GART
3 Cross references
215 Possible Orthologues:

Plasminogen

Ensembl ID : ENSMMMG00000009428
Gene Symbol: PLG
2 Cross references
239 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSMMMG00000004482
Gene Symbol: PLAT
3 Cross references
204 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSMMMG00000013184
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSMMMG00000020466
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSMMMG00000019362
Gene Symbol: PDGFRB
3 Cross references
247 Possible Orthologues:

Platelet Glycoprotein Vi-Like

Ensembl ID : ENSMMMG00000002488
Gene Symbol: LOC107158862
2 Cross references
131 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSMMMG00000023226
Gene Symbol: PLK1
3 Cross references
182 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSMMMG00000014390
Gene Symbol: PLK4
3 Cross references
208 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSMMMG00000024069
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSMMMG00000001228
Gene Symbol: PARP2
3 Cross references
185 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSMMMG00000001555
Gene Symbol: PARP3
3 Cross references
199 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).